A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease

Wouter Derks, Julian Rode, Sofia Collin, Fabian Rost, Paula Heinke, Anjana Hariharan, Lauren Pickel, Irina Simonova, Enikő Lázár, Evan Graham, Ramadan Jashari, Michaela Andrä, Anders Jeppsson, Mehran Salehpour, Kanar Alkass, Henrik Druid, Christos P. Kyriakopoulos, Iosif Taleb, Thirupura S. Shankar, Craig H. Selzman, Hesham A. Sadek, Stefan Jovinge, Lutz Brusch, Jonas Frisén, Stavros G. Drakos, Olaf BergmannCirculation 2024 · DOI

TL;DR

In failing human hearts, cardiomyocyte renewal is drastically reduced, with DNA synthesis primarily driven by polyploidization and binucleation rather than new cell formation. However, mechanical unloading via LVAD support in patients with improved cardiac function significantly boosts cardiomyocyte renewal, suggesting a latent regenerative capacity that can be therapeutically harnessed.

What Problem Does This Paper Address?

Heart failure, a leading cause of morbidity and mortality, often results from the loss of cardiomyocytes. While the adult human heart has a known, albeit slow, capacity for cardiomyocyte renewal (around 0.5% annually), it has been unclear whether this capacity is utilized or even present in the context of heart failure. Previous claims of massive regeneration in failing hearts have been difficult to reproduce. This study aims to definitively quantify cardiomyocyte renewal in advanced heart failure, both with and without mechanical circulatory support (LVAD), to understand if and how this regenerative potential can be reactivated.

Methods

The core of this study relies on a sophisticated technique called retrospective 14C birth dating. This method leverages the spike in atmospheric 14C levels from nuclear bomb testing during the Cold War. By measuring the 14C concentration in the genomic DNA of cardiomyocytes, researchers can estimate when that DNA was synthesized. Since cardiomyocytes are long-lived and typically do not divide in adults, their DNA should reflect the 14C levels present at their "birth" (i.e., the time of their formation).

Key methodological steps included:

  • Tissue Collection and Preparation: Heart tissue was obtained from various European and US institutions, including from patients undergoing LVAD implantation and from deceased donors.
  • Cardiomyocyte Nuclei Isolation and Sorting: Cardiomyocyte nuclei were isolated and sorted using fluorescence-activated cell sorting (FACS) based on the marker PCM1.
  • DNA Extraction and 14C Measurement: DNA was extracted from sorted nuclei, and 14C concentrations were measured using accelerator mass spectrometry (AMS).
  • Mathematical Modeling: A population balance equation and a Bayesian inference framework were used to model 14C dynamics and estimate cell renewal rates over time, accounting for different phases of disease and treatment. This model allowed for the differentiation between cell renewal (proliferation) and other forms of DNA synthesis like polyploidization and binucleation.
  • Histological and Echocardiographic Analysis: Standard histological techniques (WGA staining) and echocardiography were used to assess cardiac structure, function, and patient characteristics.

Datasets

The study utilized heart tissue samples from:

  • 52 patients with advanced heart failure (28 of whom received LVAD support).
  • Healthy control subjects (data from previous studies by Bergmann et al. were also incorporated).

No new datasets or benchmarks were introduced; the study focused on analyzing existing human tissue samples with a novel application of 14C dating and mathematical modeling.

Key Insights and Ideas

  • Heart Failure Stifles Renewal: The most striking finding is that in end-stage heart failure, cardiomyocyte renewal is drastically reduced, occurring at rates 18 to 50 times lower than in healthy hearts.
  • DNA Synthesis ≠ Renewal: In failing hearts, increased DNA synthesis is not due to new cardiomyocyte formation but primarily to polyploidization (cells with multiple sets of chromosomes) and binucleation (cells with two nuclei). This suggests a cellular response to stress that doesn't lead to functional cell replacement.
  • LVADs Unlock Regeneration: Mechanical unloading and functional improvement achieved through LVAD support in "responder" patients (those showing significant LVEF improvement) dramatically increases cardiomyocyte renewal. This renewal rate was found to be approximately 6-fold higher than in healthy hearts.
  • Latent Potential: This suggests that cardiomyocytes possess a latent regenerative potential that can be reactivated under specific conditions, particularly when cardiac function is improved and mechanical stress is reduced.
  • Reverse Remodeling is Key: The study links this increased renewal to reverse remodeling, a process where the heart structure and function improve after LVAD implantation.

Key Results

  • Renewal Rates:
    • Healthy hearts: ~0.55% per year.
  • NICM (Non-ischemic Cardiomyopathy) patients (pre-LVAD): ~0.03% per year (18x lower than healthy).
  • ICM (Ischemic Cardiomyopathy) patients (pre-LVAD): ~0.01% per year (50x lower than healthy).
  • LVAD responders: ~3.1% per year (6x higher than healthy).
  • DNA Synthesis Breakdown: In failing hearts without LVAD, >99.5% of DNA synthesis is attributed to polyploidization and multinucleation. In LVAD responders, cell renewal accounts for ~29.7% of DNA synthesis, while binucleation and polyploidization contribute the rest.
  • Ploidy and Binucleation: Cardiomyocytes in NICM and ICM patients show significantly higher levels of nuclear ploidy and binucleation compared to healthy hearts.

Limitations and Future Work

  • Limited Sample Size for LVAD Responders: While the study provides compelling evidence, the number of LVAD responders analyzed for specific parameters was relatively small, which the authors acknowledge.
  • Causality: While the study demonstrates a strong correlation between LVAD support, functional improvement, and increased cardiomyocyte renewal, establishing a definitive causal relationship is complex due to the multifactorial nature of cardiac recovery.
  • Future Directions: The authors emphasize that these findings highlight a significant latent cardiomyocyte regenerative potential in advanced heart failure. This opens avenues for future research to:
  • Unravel the precise molecular mechanisms regulating this process.
  • Develop pharmaceutical strategies to therapeutically stimulate cardiomyocyte renewal and promote myocardial recovery.
  • Investigate whether similar regenerative potential exists in other forms of heart disease or injury.

Summary updated

Abstract

Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.
BibTeX
@inproceedings{derks2024latent,
  author = {Wouter Derks and Julian Rode and Sofia Collin and Fabian Rost and Paula Heinke and Anjana Hariharan and Lauren Pickel and Irina Simonova and Enikő Lázár and Evan Graham and Ramadan Jashari and Michaela Andrä and Anders Jeppsson and Mehran Salehpour and Kanar Alkass and Henrik Druid and Christos P. Kyriakopoulos and Iosif Taleb and Thirupura S. Shankar and Craig H. Selzman and Hesham A. Sadek and Stefan Jovinge and Lutz Brusch and Jonas Frisén and Stavros G. Drakos and Olaf Bergmann},
  title = {{A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease}},
  booktitle = {Circulation},
  year = {2024},
  doi = {10.1161/circulationaha.123.067156},
}
Figure